Johnson & Johnson Recognized on IP SHANGHAI Global Communication Best Practices List for Driving High-Quality Development and Supporting 'Healthy China'

Johnson & Johnson China Innovation Engine Supports China's High-Quality Development and Healthy China Construction

ShanghaiNovember 8, 2022PR Newswire -- Today, at the fifth China International Import Expo,The First "In Shanghai, for the world: The "IP SHANGHAI Global Communication Best Practice List of Corporate Cases" was officially announced. As a globally leading diversified innovative healthcare enterprise,Johnson & Johnson "Based in Shanghai, radiating globally,"Johnson & Johnson China Innovation Engine" Communication CaseRanked on the List, highlighting the company's innovative leadership and influence, and affirming the positive contributions made over the years through high-quality innovative healthcare solutions to meet the health needs of the Chinese people, promote the development of China's public health sector, and support the construction of "Healthy China."

This selection was conducted byThe Shanghai Municipal Publicity Department and the Shanghai Municipal Foreign Publicity Office jointly established the Shanghai Urban Image Resource Sharing Platform (IP SHANGHAI）Jointly initiated with the Global Communication Case Management Platform of Shanghai International Studies University, a total of 50 Chinese and foreign-funded enterprises were selected, including about 30 multinational corporations. As the largest economic city in China, Shanghai is one of the most economically dynamic, open, and innovative cities in the country. According to data from the Shanghai Municipal Statistics Bureau, by the end of March 2022, Shanghai had established a cumulative total of 846 regional headquarters of multinational companies and 512 foreign-funded research and development centers.

As one of the earliest multinational enterprises to enter China after the reform and opening up, Johnson & Johnson has been rooted in China for 37 years, witnessing and participating in the rapid development of China's medical and health care industry. Currently, Johnson & Johnson’s China headquarters is located in Shanghai, deeply integrated into the construction of Shanghai as a "globally influential science and technology innovation center."

In 2019, members of the Johnson & Johnson Executive Committee, the company's highest management body, came to China and announced that China would be positioned as"Global Innovation Engine"Johnson & Johnson has become the first Fortune 500 leading healthcare enterprise to strategically deploy its global innovation capabilities in the Chinese market. Thus,China is not only one of the fastest-growing markets for Johnson & Johnson globally, but it has also become a key market for the company's innovation strategy.

Johnson & Johnson CEO Joaquin Duato (left) and Johnson & Johnson Global Senior Vice President, China Chairman Song Weiqun (center) jointly launched Johnson & Johnson's Innovation Engine in China.

While innovating forward, Johnson & Johnson is also committed to the development of public health in China. In 2021, Johnson & Johnson announcedThree Major Strategies, Six Key Measures to Help Build ""Common Prosperity""Health Defense Line," becoming the first world-leading multinational enterprise to announce support for "Common Prosperity."

Johnson & Johnson Global Senior Vice President and China Chairman Song Weiqun (center), Alain Raynaud, President of Janssen China (left), and Wang Liping, Chairman of Johnson & Johnson Global Community Impact in China, jointly announced Johnson & Johnson China's commitment to the "Common Prosperity" goal.

At the 5th CIIE, Johnson & Johnson specially established a "Co-creating a Healthy Society" section at its main booth in Hall 7.2, and through its press conference, showcased the company’s efforts and progress in supporting the Chinese government to promote balanced and inclusive access to quality medical resources, enhance the health and well-being of Chinese citizens, and advance the process of achieving "common prosperity."

Based in Shanghai, Rooted in China

Shanghai is the location of Johnson & Johnson's China headquarters, as well as an important research and development center and supply chain manufacturing base for the company. Using this as a magnetic center, Johnson & Johnson continuously...Global resources, industry experience, innovative products and services, and advanced high-end smart manufacturing capabilitiesBring to China, serving the health needs of 1.4 billion Chinese people, and contributing to the construction of "Healthy China".

In 2020, against the backdrop of the COVID-19 pandemic, Johnson & Johnson actively fulfilled its mission and responsibility as an industry leader on a global scale, strengthening communication and collaboration. Dr. Paul Stoffels, then Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson, held a transoceanic video conference with Academician Zhong Nanshan, head of the National Health Commission's high-level expert group, and Professor Zhang Wenhong, head of Shanghai's COVID-19 medical treatment expert group, to discuss accelerating innovative cooperation and jointly addressing global public health challenges.

February 2022,Johnson & Johnson's pharmaceutical subsidiary, Janssen China, signed a strategic cooperation Memorandum of Understanding with the National Center for Infectious Diseases and the Shanghai Huashen Microbiology and Infection Research Institute., aiming to promote the continuous development of the anti-infective field, improve public health standards, and contribute to the construction of "Healthy China 2030". In March,The company signed a Strategic Partner Program Intent with the Chinese Center for Disease Control and Prevention., and carry out cooperation in two key areas: the capacity building of disease control personnel and the research on the disease control policy system at the industry level, supporting public welfare related to disease control.

In 2022, Janssen China, a pharmaceutical subsidiary of Johnson & Johnson, reached a strategic cooperation with the National Center for Infectious Diseases Medicine.

Innovative Ecosystem, Co-Building and Sharing

For a long time,"Collaborating with partners from the government, industry, and academia""Co-create, Co-build, and Share" the innovative healthcare ecosystem has always been the core development philosophy of Johnson & Johnson.

Johnson & Johnson's medical technology, pharmaceutical, and consumer health businesses all have research and development centers or departments in China.China is also the only market outside the United States where all Johnson & Johnson businesses have local R&D teams.。

In 2014, Johnson & Johnson established one of its four global innovation platforms, the Asia-Pacific Innovation Center, in Shanghai. Johnson & Johnson Innovation has continued to deepen its presence in China, nurturing outstanding early-stage innovations in fields such as oncology, infectious diseases, immunology, neuroscience, vaccines, cardiovascular and metabolic health, public health, and medical technology. It accelerates innovation through collaborations with startups, scientists, and university research institutions, including R&D partnerships, strategic venture investments, and company incubation. In 2019, Johnson & Johnson, in collaboration with the Pudong New Area government and Shanghai Zhangjiang Pharma Valley Public Service Platform Co., Ltd., set up the world's largest and Asia’s first innovation incubator in Shanghai.JLABS @ ShanghaiOver the past few years, more than 70 startups have moved into JLABS @ Shanghai,The total value obtained by the入驻企业exceeds$3.5 Billion in Financing and Strategic Relationships. With a strong innovation network and fruitful achievements in promoting scientific research innovation and driving innovative cooperation, in 2021,Johnson & Johnson Becomes the First Company Recognized by the Shanghai Municipal Government as an Open Innovation Platform。

Johnson & Johnson's Largest Global, First and Only Innovative Incubator in Asia - JLABS @ Shanghai

Innovation from China, Radiating Globally

Johnson & Johnson actively builds the Chinese market into an innovation center with global influence by means of asset acquisition, close cooperation with upstream and downstream enterprises in the industrial chain, etc.Biopharmaceuticals,AI Artificial Intelligence, 5G, Robotics, DigitalizationRadiate globally as a leader.

In the field of medical technology,Johnson & Johnson collaborates with local orthopedic robotics companies to develop digital intelligent solutions, aiming to enhance patient care and support orthopedic surgeons in improving surgical efficiency and standardizing procedures to a higher level.. At the same time, the company alsoIncrease Collaboration with Innovative Local EntitiesCollaboration with AI medical technology companies to promote the application of cutting-edge technologies such as artificial intelligence, machine learning, and big data in innovative digital orthopedic solutions. Committed to covering the entire course of orthopedic and surgical procedures with intelligent and precise clinical solutions, creating a patient-centered digital surgery ecosystem.。

In order to help more young doctors continuously improve their skills and enhance the accessibility of high-quality medical care, Johnson & Johnson Medical TechnologiesA case review software system applicable to atrial fibrillation radiofrequency ablation has been developed using technologies such as artificial intelligence and machine learning.(AIFV). This system can extract raw data from Johnson & Johnson's 3D electrophysiology navigation system and quickly generate intelligent analysis reports,Provide doctors with more objective and accurate surgical review tools to shorten the clinical learning curve., helping doctors more accurately control each surgery and serve more patients. In3D Printing Field, The R&D team in China has also collaborated with the supply chain team to establish end-to-end R&D, production, and delivery capabilities.

In the pharmaceutical field, for multiple myeloma,Johnson & Johnson Collaborates Globally with Chinese Biopharmaceutical Innovation Company Legend Biotech, and have made significant breakthroughs together in the development of CAR-T therapy. Currently,This innovative therapy has been approved for marketing or conditional marketing by regulatory agencies in the United States, the European Union, and Japan., achieving a new milestone and breakthrough in the internationalization of China's innovative drugs.

Song Weiqun, Global Senior Vice President of Johnson & Johnson and Chairman of the China Region"It reflects that the concept of innovative development and win-win cooperation has been rooted in Johnson & Johnson’s more than 130 years of development history, and also guides our growth alongside China's healthcare industry. Johnson & Johnson highly values the Chinese market, continuously deepens its high-quality development in China, and collaborates with partners from all sectors to assist the government in building an open medical innovation ecosystem. Looking ahead, we look forward to continuing to work with the government and all partners, driven by innovation, to jointly create a bright future of open collaboration and innovative development, sharing new opportunities brought by the times, and contributing to the modernization of China’s economic and social development."